Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | RGS12 | O14924 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663881 | 0.86 | KDM4E (0.58) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL3670392 | 0.86 | KDM4E (0.55) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL3433597 | 0.85 | KDM4E (0.54) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL6356581 | 0.83 | KDM4E (0.49) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL10510940 | 0.82 | MTNR1A (0.55) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL18247 | 0.80 | PNP (0.59) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL2776452 | 0.80 | PNP (0.49) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL10505519 | 0.79 | PNP (0.49) | PNPKDM4EMEN1KMT2AUSP2 | |
| SCHEMBL1980958 | 0.78 | PNP (0.57) | PNPKDM4EMEN1KMT2AMAPT | |
| SCHEMBL6359276 | 0.78 | PNP (0.64) | PNPMEN1KMT2AALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6436945-B2 | FOR ENHANCING THE CHEMOTHERAPEUTIC TREATMENT OF TUMOR CELLS IN A MAMMAL WITH AN ANTINEOPLASTIC ALKYLATING AGENT, WHICH CAUSES CYTOTOXIC LESIONS AT THE O6-POSITION OF GUANINE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT) INACTIVATOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF HEALTH AND HUMAN SERVICES | 2002-08-20 | — | — | US | disclosed |
| US-6333331-B1 | USEFUL IN INACTIVATING THE HUMAN DNA REPAIR PROTEIN O.SUP.6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-12-25 | — | — | US | disclosed |